✦ LIBER ✦

Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

✍ Scribed by Jennifer C. Livaudais; Dawn L. Hershman; Laurel Habel; Lawrence Kushi; Scarlett Lin Gomez; Christopher I. Li; Alfred I. Neugut; Louis Fehrenbacher; Beti Thompson; Gloria D. Coronado

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 201 KB
Volume: 131
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1762-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Optimizing aromatase inhibitor integrati

Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer

✍ Rowan T. Chlebowski 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 274 KB

Predictors of timing of adjuvant chemoth

Predictors of timing of adjuvant chemotherapy in older women with hormone receptor–negative, stages II–III breast cancer

✍ Stephanie B. Wheeler; William R. Carpenter; Jeffrey Peppercorn; Anna P. Schenck; 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 215 KB

Prognostic factors of early distant recu

Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis

✍ Marc Debled; Gaëtan MacGrogan; Véronique Brouste; Simone Mathoulin-Pelissier; Mi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Current adjuvant hormone therapy in postmenopausal women with breast cancer is debatable between upfront aromatase inhibitors (AIs) and sequential treatment with tamoxifen. A major concern is the higher rate of early recurrences observed with sequential treatment. The aut

Vitamin D intake may be a predictor of r

Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer

✍ Omer Dizdar; Nilufer Bulut; Kadri Altundag 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 84 KB

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br